Improvement in radiosensitivity using small interfering RNA targeting p53R2 in esophageal squamous cell carcinoma

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 561-567

  Yokomakura, Naoya ^a   Natsugoe, Shoji ^a   Okumura, Hiroshi ^a   Ikeda, Ryuji ^a   Uchikado, Yasuto ^a   Mataki, Yuko ^a   Takatori, Hiroyuki ^a   Matsumoto, Masataka ^a   Owaki, Tetsuhiro ^a   Ishigami, Sumiya ^a   Aikou, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Esophageal squamous cell carcinoma; p53R2; Radiosensitivity; Small interfering RNA

Indexed keywords

CELL CYCLE PROTEIN; COMPLEMENTARY DNA; DNA; OLIGODEOXYRIBONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; RRM2B PROTEIN, HUMAN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BIOPSY; ESOPHAGUS TUMOR; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

BIOPSY; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA, COMPLEMENTARY; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING;

EID: 38449101066     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.561     Document Type: Article

References (28)

1. Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS and Wong J: Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg 238: 339-348, 2003. (Pubitemid 38174477)
2. Rosa AR, Gurski RR, Schirmer CC, Brentano L and Kruel CD: Survival and prognostic factors in patients with resected epidermoid oesophageal carcinoma. Int Surg 84: 193-198, 1999.
3. Okumura H, Natsugoe S, Matsumoto M, et al: The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 92: 284-289, 2005. (Pubitemid 40343142)
4. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Ishigami S, Owaki T and Aikou T: Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 13: 697-701, 2005.
5. Tanaka H, Arakawa H, Yamaguchi T, et al: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49, 2000. (Pubitemid 30143125)
6. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y and Arakawa H: p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61: 8256-8262, 2001. (Pubitemid 33091620)
7. Bernstein E, Caudy AA, Hammond SM and Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366, 2001. (Pubitemid 32151243)
8. Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200, 2001. (Pubitemid 32107664)
9. Hamilton AJ and Baulcombe DC: A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286: 950-952, 1999.
10. Hammond SM, Bernstein E, Beach D and Hannon GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296, 2000. (Pubitemid 30163547)
11. Zamore PD, Tuschl T, Sharp PA and Bartel DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33, 2000.
12. Dorsett Y and Tuschl T: siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3: 318-329, 2004. (Pubitemid 38499759)
13. Lieberman J, Song E, Lee SK and Shankar P: Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 9: 397-403, 2003. (Pubitemid 37169054)
14. Sobin LH and Fleming ID: Union Internationale Contre le Cancer and the American Joint Committee on Cancer. TNM Classification of Malignant Tumors. 5th edition. Cancer 80: 1803-1804, 1997.
15. Japanese Society for Esophageal Diseases: Guide Lines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9th edition. Kanehara & Co., Ltd., Tokyo, 1999.
16. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R and Hainaut P: Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 71: 79-87, 1997. (Pubitemid 27158413)
17. Itoshima T, Fujiwara T, Waku T, et al: Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res 6: 2851-2859, 2000. (Pubitemid 30482127)
18. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991. (Pubitemid 21917115)
19. Levine AJ: The tumor suppressor genes. Annu Rev Biochem 62: 623-651, 1993.
20. Nakano K, Balint E, Ashcroft M and Vousden KH: A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19: 4283-4289, 2000.
21. Fire A: RNA-triggered gene silencing. Trends Genet 15: 358-363, 1999.
22. Hammond SM, Caudy AA and Hannon GJ: Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2: 110-119, 2001. (Pubitemid 33674002)
23. Sharp PA: RNA interference. Genes Dev 15: 485-490, 2001.
24. Tuschl T: RNA interference and small interfering RNAs. Chembiochem 2: 239-245, 2001.
25. Song E, Lee SK, Wang J, et al: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351, 2003. (Pubitemid 36362792)
26. Shen C, Buck AK, Liu X, Winkler M and Reske SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett 539: 111-114, 2003. (Pubitemid 36351297)
27. Sioud M and Sorensen DR: Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312: 1220-1225, 2003. (Pubitemid 37490947)
28. Yano J, Hirabayashi K, Nakagawa S, et al: Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 10: 7721-7726, 2004. (Pubitemid 39557537)